• A
  • A
Font Size

A simple vision test that looks like graph paper with a dot in the middle. May be used at home as a tool to monitor vision between eye care appointments.

A treatment for MEfRVO designed to block VEGF (a protein made by the blood vessels that, at high levels, can cause abnormal blood vessels to grow in the eye and leak fluid).

Hardening of the arteries.

An eye disease in which a blood clot blocks one or more veins branching out from the central retinal vein (the main vein that drains blood away from the retina), causing fluid to leak into the retina.

An eye disease in which a blood clot blocks the central retinal vein (the main vein that drains blood away from the retina), causing fluid to leak into the retina.

An exam for checking the back of the eye, including the retina, for signs of problems or changes. To see into the back of the eye, the doctor puts drops into the eye to dilate (widen) the pupil.

A chart for measuring visual acuity (how well a person sees) that has rows of letters that get smaller from top to bottom. A person reads the smallest letters seen. The more letters seen, the better the vision.

A test in which dye is used to show the blood vessels in the back of the eye.

A test in which a special camera takes photos showing the inside of the back of the eye.

High pressure in the eye.

A doctor trained to give low vision examinations and prescribe low vision devices and services.

The part of the retina responsible for sharp central vision.

When the macula of the eye swells with fluid.

A test that shows the layers and thickness of the retina.

The opening that controls the amount of light entering the eye.

The light-sensitive tissue at the back of the eye.

A protein made by the blood vessels that, at high levels, can cause abnormal blood vessels to grow in the eye and leak fluid.

Measures how well you see the letters on an eye chart from a distance.

Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
Top
Important Safety Information
  • EYLEA® (aflibercept) Injection is a prescription medication administered by injection into the eye. You should not use EYLEA if you have an infection in or around the eye, eye pain or redness, or known allergies to any of the ingredients in EYLEA, including aflibercept.
  • Injection into the eye with EYLEA can result in an infection in the eye and retinal detachment (separation of retina from back of the eye). Inflammation in the eye has been reported with the use of EYLEA.
  • In some patients, injections with EYLEA may cause a temporary increase in eye pressure within 1 hour of the injection. Sustained increases in eye pressure have been reported with repeated injections, and your doctor may monitor this after each injection.
  • There is a potential risk of serious and sometimes fatal side effects related to blood clots, leading to heart attack or stroke in patients receiving EYLEA.
  • Serious side effects related to the injection procedure with EYLEA are rare but can occur including infection inside the eye and retinal detachment.
  • The most common side effects reported in patients receiving EYLEA are increased redness in the eye, eye pain, cataract, moving spots in the field of vision, increased pressure in the eye, and vitreous (gel-like substance) detachment.
  • It is important that you contact your doctor right away if you think you might be experiencing any side effects, including eye pain or redness, light sensitivity, or blurring of vision, after an injection.
  • EYLEA is for prescription use only. For additional safety information, please talk to your doctor and see the full Prescribing Information for EYLEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Indications

EYLEA® (aflibercept) Injection is a prescription medicine approved for the treatment of patients with:

  • Wet Age-related Macular Degeneration (AMD): The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 3 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 3 months (12 weeks).
  • Macular Edema following Retinal Vein Occlusion (RVO): The recommended dose for EYLEA is 2 mg administered by injection in the eye monthly (every 4 weeks).
  • Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR) in patients with DME: The recommended dose for EYLEA is 2 mg administered by injection in the eye every 2 months (8 weeks) following 5 initial monthly (every 4 weeks) injections. EYLEA may be dosed once per month, but in most patients, additional benefit was not seen with this dosing plan. Some patients may need monthly (every 4 weeks) dosing after the first 5 months (20 weeks).
Please see the full Prescribing Information for EYLEA.

The information contained herein is provided for general educational purposes. If you have any questions, talk to your doctor.